Gaudium IVF and Women Health Limited — Investor Meet, 19-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Gaudium IVF and Women Health Limited held an earnings conference call to discuss the financial results for the quarter ended June 30, 2026.

**Financial Performance:**

Revenue for Q1 FY27 rose 9.1% YoY to ₹19.4 Cr. EBITDA and PAT stood at ₹2.4 Cr and ₹1.8 Cr, respectively, reflecting investments in expansion. Excluding one-off expansion costs, EBITDA would have been approx. ₹5.35 Cr with a margin of 27.63%.

**Management Commentary & Outlook:**

Management highlighted strong clinical outcomes, with a first-attempt pregnancy success rate growing to 62%. The company is rolling out 10 new hubs in FY27, with one already operational and two more nearing launch. International spokes are progressing, supporting medical tourism. The company is on track to meet FY27 revenue targets, projecting 30% YoY growth.

**Strategic Themes & Operational Updates:**

The company is a first mover in India with AI-led embryology tools (SiD and ERICA), showing an ~8% improvement in first-attempt outcomes. A new Gaudium Signature Lab has launched in South Extension, Delhi, with plans to replicate this model across new centers. Board approval was received for a Women's Hospital in Lucknow, to be funded by internal accruals.

**Analyst Q&A Highlights:**

Discussions covered the seasonality of Q1, the rationale for the hospital business expansion, and the traction of older centers. Management clarified that the average revenue per patient, excluding minimal services, is ₹4 Lakhs. Capex per hub is ₹2.5 Cr, with projected revenues of ₹2 Lakhs per cycle.

**Investor Angle:**

Gaudium IVF is well-positioned for growth with its clinician-led, SOP-driven model, AI integration, and expansion plans in an underpenetrated market. The company maintains a confident tone regarding its FY27 prospects.